Immunization, Hib3 in Colombia
Colombia: Immunization, Hib3 was 89.0% in 2024. ▲ Rising
Immunization, Hib3 in Colombia, 1998–2024
Source: WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/). Measured in % of children ages 12-23 months.
Analysis
In 2024, immunization, hib3 in Colombia stood at 89.0%.
Compared with earlier readings it is down 1.1% on the previous year and down 1.1% over ten years.
Over the whole period, immunization, hib3 in Colombia peaked at 94.0% in 2007 and was at its lowest, 55.0%, in 2001.
Colombia ranks 108th of 191 countries on this measure, in the middle of the range.
The long-run direction has been consistently rising across the 27 years of available data.
Immunization, Hib3 in Colombia, year by year
| Year | % of children ages 12-23 months | Change |
|---|---|---|
| 1998 | 62.0% | — |
| 1999 | 64.0% | +3.2% |
| 2000 | 65.0% | +1.6% |
| 2001 | 55.0% | -15.4% |
| 2002 | 69.0% | +25.5% |
| 2003 | 93.0% | +34.8% |
| 2004 | 89.0% | -4.3% |
| 2005 | 93.0% | +4.5% |
| 2006 | 93.0% | +0.0% |
| 2007 | 94.0% | +1.1% |
| 2008 | 92.0% | -2.1% |
| 2009 | 92.0% | +0.0% |
| 2010 | 88.0% | -4.3% |
| 2011 | 85.0% | -3.4% |
| 2012 | 92.0% | +8.2% |
| 2013 | 91.0% | -1.1% |
| 2014 | 90.0% | -1.1% |
| 2015 | 91.0% | +1.1% |
| 2016 | 91.0% | +0.0% |
| 2017 | 92.0% | +1.1% |
| 2018 | 92.0% | +0.0% |
| 2019 | 92.0% | +0.0% |
| 2020 | 88.0% | -4.3% |
| 2021 | 87.0% | -1.1% |
| 2022 | 87.0% | +0.0% |
| 2023 | 90.0% | +3.4% |
| 2024 | 89.0% | -1.1% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 1990s | 63.0% | 62.0% | 64.0% | 2 |
| 2000s | 83.5% | 55.0% | 94.0% | 10 |
| 2010s | 90.4% | 85.0% | 92.0% | 10 |
| 2020s | 88.2% | 87.0% | 90.0% | 5 |
Countries ranked near Colombia
- 108 Burundi 89.0% compare
- 108 Lithuania 89.0% compare
- 108 Netherlands 89.0% compare
- 108 New Zealand 89.0% compare
- 108 Nicaragua 89.0% compare
More health data for Colombia
- Un projection of annual infant deaths, annual growth rate -1.83 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.3468 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,505 deaths per 1,000 people (2090)
- Number of infants who die before age 1 698 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 1 (2025)
- Population ages 00-04, female, annual growth rate -0.3706 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0324 units per person (2025)
- Population ages 00-04, male, annual growth rate -0.3776 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is immunization, hib3 in Colombia?
- Immunization, hib3 in Colombia was 89.0% in 2024, according to WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).
- What is the highest immunization, hib3 recorded in Colombia?
- The highest recorded value was 94.0% in 2007.
- What is the lowest immunization, hib3 recorded in Colombia?
- The lowest recorded value was 55.0% in 2001.
- How does Colombia rank for immunization, hib3?
- Colombia ranks 108th out of 191 countries with data for 2024.
- Is immunization, hib3 rising or falling in Colombia?
- Over the last ten years it is down 1.1%. The long-run trend across the full record is rising.
- Where does this Colombia data come from?
- The figures come from WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as part of Immunization, Hib3 (% of children ages 12-23 months). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 27 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.